Introduction
============

Coronary artery disease (CAD) remains the worldwide leading cause of mortality among men and women ([@b1-br-0-0-1109]). The American Heart Association reported that in 2014 there were 364,593 mortalities from CAD in the United States ([@b2-br-0-0-1109]), based on 2014 mortality data from the National Center for Health Statistics ([@b3-br-0-0-1109]). In Japan, the Ministry of Health, Labour and Welfare has reported that the rate of mortality per 100,000 population from acute ischemic heart diseases was 71,673 in 2015 ([@b4-br-0-0-1109]). Cerebral infarction (CI) is also a serious clinical problem worldwide. In the United States, approximately 610,000 and 185,000 people experience new and recurrent stroke events each year, respectively, and it was estimated that the prevalence of silent CI ranged from 6--28% from 1993 to 2005 ([@b2-br-0-0-1109]). In 2015, the number of mortalities from CI and intracerebral hemorrhage in Japanese patients was 64,523 and 32,113, respectively ([@b4-br-0-0-1109]). Therefore, examination of CAD and CI susceptibility variants in Japanese individuals may be key to successful personalized prevention of these diseases.

Previous genome-wide association studies (GWASs) have identified a variety of genes and loci that confer susceptibility to CAD and CI across various ethnic groups, and have reported inter-ethnic differences of genetic contribution to these diseases ([@b5-br-0-0-1109]--[@b11-br-0-0-1109]). A meta-analysis using datasets of the CARDIoGRAMplusC4D, MIGen and CARDIoGRAM Exome consortia and ESP EOMI studies assessed the association of genetic variants in several chemokine receptor genes with CAD and myocardial infarction ([@b6-br-0-0-1109]). The study did not identify any evidence of an association between the genetic variants and disease in large European ancestry cohorts, whereas six low frequency variants were associated with myocardial infarction in a South Asian cohort. Another meta-analysis of two independent Chinese GWASs for CAD identified four CAD-associated loci that were not present in populations of European ancestry ([@b7-br-0-0-1109]). Inter-ethnic difference of disease susceptibility loci has also been reported in GWASs for ischemic stroke (i.e., CI). A GWAS for ischemic stroke in 6,341 Japanese individuals who participated in three independent population-based studies identified that cadherin EGF LAG seven-pass G-type receptor 1 (*CELSR1*) was a susceptibility gene for ischemic stroke ([@b10-br-0-0-1109]). The association of *CELSR1* with stroke has been confirmed in a Portuguese cohort ([@b12-br-0-0-1109]); however, the Siblings With Ischemic Stroke Study did not demonstrate an association of 312 probands with ischemic stroke from 70 centers in the USA and Canada ([@b13-br-0-0-1109],[@b14-br-0-0-1109]). The discrepancy of disease-susceptible variants among populations may be due to differences of genetic background among ethnic groups.

Although recent GWASs have identified a large number of genetic variants that confer susceptibility to cardiovascular diseases ([@b5-br-0-0-1109],[@b7-br-0-0-1109],[@b9-br-0-0-1109],[@b14-br-0-0-1109],[@b15-br-0-0-1109]), they have been conducted in a cross-sectional manner that commonly measures traits at a single point in time. To address this issue, the present study examined disease progression and physiological changes in 5,989 Japanese individuals who had annual health check-ups for several years, and performed longitudinal exome-wide association studies (EWASs) to investigate novel susceptibility loci for CAD and CI.

Materials and methods
=====================

### Study subjects

The physiological data of 6,026 community-dwelling individuals recruited to a population-based cohort study (Inabe Health and Longevity Study) in Inabe City, Japan was traced ([@b16-br-0-0-1109]--[@b20-br-0-0-1109]). These individuals visited Inabe General Hospital for an annual health check-up, with a mean annual follow-up period of 5±3 years (covering April 2003 to March 2014). All participants had undergone 1 to 11 medical examinations. This cohort was denoted as the 'Inabe cohort' in the longitudinal EWASs. Detailed methods for the recruitment of subjects and for the collection and storage of medical examination data and genomic DNA samples have been described previously ([@b19-br-0-0-1109]). Diagnostic criteria for CAD and CI have also been described previously ([@b18-br-0-0-1109]).

The study protocol complied with the Declaration of Helsinki and was approved by the Committees on the Ethics of Human Research of Mie University Graduate School of Medicine and Inabe General Hospital (Inabe, Japan). Written informed consent was obtained from all subjects prior to enrollment in the Inabe Health and Longevity Study.

### Longitudinal EWAS

Infinium HumanExome-12 ver. 1.2 BeadChip and Infinium Exome-24 ver. 1.0 BeadChip (Illumina, Inc., San Diego, CA, USA) were used to genotype \~244,000 genetic variants in the Inabe cohort for longitudinal EWASs. These arrays include putative functional exonic variants selected from \>12,000 individual exome and whole-genome sequences across diverse ethnic populations, including European, African, Chinese and Hispanic individuals ([@b21-br-0-0-1109]). Missing genotype or phenotype data of each individual was eliminated from the analyses. Quality control of genotyping data was performed, and monomorphic sites and the following genetic variants were discarded: i) Variants contained in only one of the exome arrays used (\~3.6% of all variants); ii) variants with a call rate of \<97.0%; iii) variants with a minor allele frequency (MAF) of \<0.05; iv) variants whose genotype distribution significantly deviated from Hardy-Weinberg equilibrium (P\<0.001) in controls; and v) variants located on mitochondrial DNA or sex chromosomes.

In addition, sex specification was checked for each sample, with samples for which the sex designation in the clinical records was inconsistent with genetic sex discarded. Cryptic relatedness and duplicate samples were checked by calculation of identity by descent (IBD); all pairs of DNA samples exhibiting an IBD of \>0.1875 were inspected and one sample from each pair was excluded. Population stratification in the Inabe cohort was examined by principal component analysis via the EIGENSTRAT method ([@b22-br-0-0-1109]), using JMP Genomics version 6.0 (SAS Institute, Inc., Cary, NC, USA), and four outliers were removed from the longitudinal EWASs. Consequently, a total of 24,651 single nucleotide polymorphisms (SNPs) among 5,989 Japanese individuals passed quality control for the longitudinal EWASs of CAD and CI. The rearrangement of Inabe longitudinal data was conducted using R software version 3.32 ([@b23-br-0-0-1109]) via RStudio version 1.0.136 (<http://www.rstudio.com/>) ([@b24-br-0-0-1109]) and Perl script (version 5.26.2; <https://www.perl.org/get.html>). Using JMP Genomics, genotyping data were converted into numeric data for dominant, additive and recessive inheritance models. The dominant and recessive models were defined as '0, AA; 1, AB + BB' and '0, AA + AB; 1, BB' (A, major allele; B, minor allele), respectively, whereas the additive model was defined as '0, AA; 1, AB; 2, BB'.

### Statistical analysis

Longitudinal EWASs were conducted for 5,713 control individuals, 170 subjects with CAD, and 117 with CI ([Table I](#tI-br-0-0-1109){ref-type="table"}). The association of the prevalence of CAD and CI with SNPs was tested by the generalized estimating equation (GEE) model ([@b25-br-0-0-1109],[@b26-br-0-0-1109]) with adjustments for age, sex, body mass index (BMI), smoking and prevalence of hypertension, type 2 diabetes mellitus and dyslipidemia, using the R package 'geepack' ([@b27-br-0-0-1109]). Since the prevalence of CAD and CI is repeated categorical data (case or control), a binomial distribution was applied for assessing the association between the categorical outcomes and SNPs in the GEE method. The waves argument was used to specify the ordering of repeated measurements within individuals. Effects of SNPs in exome arrays on CAD or CI are not independent as many SNPs are in linkage disequilibrium (LD) ([@b13-br-0-0-1109],[@b28-br-0-0-1109],[@b29-br-0-0-1109]). Therefore, the false discovery rate (FDR) was calculated using the Benjamin and Hochberg method ([@b30-br-0-0-1109]) to compensate for multiple comparison of genotypes with the phenotypes. An FDR of \<0.05 was considered to indicate a statistically significant association.

A small effective sample size may increase the probability of generating false positives (type I errors) ([@b31-br-0-0-1109]). Sitlani *et al* ([@b31-br-0-0-1109]) recommend the use of approxdf, which is a scale of small effective sample size: Approxdf = 2 × MAF × Nindep, where Nindep is the sum of the estimated number of independent observations per person. They demonstrated that an approxdf of ≥10 could reduce type I errors. Thus, approxdf was computed by the R package 'bosswithdf' ([@b31-br-0-0-1109],[@b32-br-0-0-1109]). To avoid the issue of false positive association in small sample sizes, a strict approxdf threshold was applied, and SNPs with approxdf ≤30 discarded.

### LD estimates and prediction of functional association for candidate loci

To survey LDs between the candidate SNPs detected in the present study and previously identified CAD- or CI-associated SNPs in JPT (Japanese in Tokyo, Japan) from the 1000 Genomes Project \[<http://www.1000genomes.org/> ([@b33-br-0-0-1109])\], analyses were conducted using the LDproxy of LDlink \[<https://analysistools.nci.nih.gov/LDlink/> ([@b34-br-0-0-1109])\], which is a web-based application. The association of SNPs with CAD or CI reported by previous studies was investigated using the Genome-Wide Repository of Associations Between SNPs and Phenotypes \[GRASP; <https://grasp.nhlbi.nih.gov/Overview.aspx> ([@b35-br-0-0-1109])\], DisGeNET \[<http://www.disgenet.org/web/DisGeNET/> ([@b36-br-0-0-1109])\] and GWAS Catalogue \[<https://www.ebi.ac.uk/gwas/> ([@b37-br-0-0-1109])\] databases. Gene-gene functional interactions were predicted using the GeneMANIA Cytoscape plugin ([@b38-br-0-0-1109]--[@b40-br-0-0-1109]) via Cytoscape version 3.4.0 software \[<http://www.cytoscape.org/> ([@b41-br-0-0-1109])\].

Results
=======

### Characteristics of subjects

The characteristics of subjects in the Inabe cohort with respect to longitudinal data are presented in [Table I](#tI-br-0-0-1109){ref-type="table"}. The prevalence of hypertension, type 2 diabetes mellitus, dyslipidemia, chronic kidney disease and hyperuricemia was higher in patients with CAD or CI than in controls. The prevalence of CAD and CI was lower in females (39 CAD and 37 CI patients) than in males (131 CAD and 80 CI patients). The majority of physiological or clinical parameters examined (age, BMI, systolic and diastolic blood pressure, fasting plasma glucose level, blood hemoglobin A~1c~ content and serum concentrations of triglycerides, creatinine, and uric acid) were higher, whereas serum concentrations of high-density lipoprotein-cholesterol and estimated glomerular filtration rate were lower, in the patients than in the controls. The serum concentration of low-density lipoprotein-cholesterol was lower in patients with CAD (2.76±0.032 mmol/l) than in controls (3.19±0.005 mmol/l). This discrepancy may be attributable to effects of lipid-lowering treatment for patients with CAD.

### Association of SNPs with longitudinal data on the prevalence of CAD

Following the quality control checks, the association between 24,651 SNPs and the prevalence of CAD in the Inabe cohort was tested by using the GEE model with adjustments for age, sex, BMI, smoking and prevalence of hypertension, type 2 diabetes mellitus and dyslipidemia. Candidate SNPs that reached statistical significance (FDR of \<0.05) were additionally screened against the threshold of approxdf (\>30). Analyses revealed that two SNPs \[rs4606855 of *ADGRE3* (P=2.5×10^−6^; FDR=0.031, approxdf=71) and rs3746414 of *ZFP64* (P=5.9×10^−6^; FDR=0.048; approxdf=93)\] and one SNP \[rs7132908 of *FAIM2* (P\<2.0×10^−16^; FDR\<4.9×10^−12^; approxdf=65)\] were significantly associated with the prevalence of CAD in additive and recessive models, respectively ([Table II](#tII-br-0-0-1109){ref-type="table"}).

According to the GRASP, DisGeNET and GWAS Catalogue databases, the association of the three SNPs with CAD has not been reported to date. Therefore, the three SNPs were identified as novel genetic variants that may confer susceptibility to CAD. The nucleotide substitution at rs7132908 in FAIM2 is predicted to be a silent substitution in the 3′-untranslated region, while the remaining two SNPs are predicted to alter amino acid residues (i.e., nonsynonymous substitutions), according to the NCBI dbSNP database \[<https://www.ncbi.nlm.nih.gov/projects/SNP/> ([@b42-br-0-0-1109])\].

Genotype distributions for rs4606855, rs3746414 and rs7132908 in subjects with CAD and controls in the longitudinal EWAS are listed in [Table III](#tIII-br-0-0-1109){ref-type="table"}. In the current study, the prevalence of CAD was lower in subjects with minor alleles than in those with major alleles for all SNPs, suggesting the CC genotype of rs4606855 and the AA genotypes of rs3746414 and rs7132908 to be protective against CAD.

### Association of SNPs with longitudinal data on the prevalence of CI

In the Inabe cohort, three SNPs \[rs6580741 of *FAM186A* (P\<2.0×10^−16^; FDR\<4.9×10^−12^; approxdf=48), rs1324015 of *LINC00400* (P\<2.0×10^−16^; FDR\<4.9×10^−12^; approxdf=49), and rs884205 of *TNFRSF11A* (P\<2.0×10^−16^; FDR\<4.9×10^−12^; approxdf=32)\] were significantly associated with the prevalence of CI in the recessive model, although the GEE tests in the dominant and additive models detected no significant association between SNPs and the prevalence of CI ([Table II](#tII-br-0-0-1109){ref-type="table"}). The CI-associated SNPs detected in the recessive model were not shared with the CAD-associated SNPs. The nucleotide substitution at rs6580741 in *FAM186A* is predicted to alter an amino acid residue ([Table II](#tII-br-0-0-1109){ref-type="table"}), whereas the substitutions at the other SNPs are predicted as silent, according to the NCBI dbSNP.

The rs6580741 of *FAM186A* is located relatively close (\~464 kb) to rs7132908 of *FAIM2* at chromosomal region 12q13.12, although these SNPs were related to the different diseases. The LD among these SNPs was thus examined among participants in the Inabe cohort using the R package 'genetics' \[<https://CRAN.R-project.org/package=genetics> ([@b43-br-0-0-1109])\]. The estimation demonstrated that these SNPs were not in LD (D\'=0.045, r^2^=0.002), suggesting that rs7132908 and rs6580741 were independently associated with the prevalence of CAD and CI, respectively.

Genotype distributions for rs6580741, rs1324015 and rs884205 in subjects with CI and controls in the longitudinal EWAS are listed in [Table IV](#tIV-br-0-0-1109){ref-type="table"}. As with the case of CAD-associated SNPs, for all three SNPs, the prevalence of CI was lower in subjects with minor alleles than in those with major alleles. The *CC* genotype of rs6580741, the *AA* genotype of rs1324015, and the *TT* genotype of rs884205 may thus be protective against CI.

### Assessment of LD between the six identified SNPs and other SNPs associated with CAD or CI

The LDs between the six candidate SNPs identified in the present study and adjacent SNPs across a \~1 Mb genomic region were assessed using the LDproxy in LDlink. The LDproxy analysis indicated that 433 SNPs were in significant LD (r^2^≥0.5) with one of the candidate SNPs in JPT from the 1000 Genomes Project ([Table V](#tV-br-0-0-1109){ref-type="table"}). Of the 433 SNPs, there were no SNPs previously identified to be associated with CAD or CI (P\>0.01) according to the GRASP database. In addition, the LDpair analysis in LDlink using allele frequency data in East Asian populations from the 1000 Genomes Project indicated that rs1324015 associated with the prevalence of CI in the present study was not in LD with rs9533425 (D\'=0.4709, r^2^=0.0007), previously reported to be associated with lag time (lag phase of the turbidimetric clotting assay) to fibrin clot formation ([@b28-br-0-0-1109]). These results suggest that effects of the candidate SNPs on the prevalence of CAD or CI are independent.

Gene interaction network analysis. To investigate the interactive functional association, a GeneMANIA network analysis was conducted of the top ten genes (high gene-disease association scores) that have been demonstrated to be associated with CAD or CI selected from the DisGeNET database, and of the five genes (*ZFP64, FAIM2, ADGRE3, FAM186A*, and *TNFRSF11A*) identified in the present study ([Fig. 1](#f1-br-0-0-1109){ref-type="fig"}). Given that *LINC00400* non-coding RNA has not been well characterized, it could not be examined. The network analysis showed that the CAD- and CI-associated genes identified in the present study have potential direct or indirect interactions with several genes previously demonstrated to be associated with CAD and CI, respectively. The network suggested that *ZFP64* and *FAIM2* interact with *LOX* and both *CRP* and *APOB*, respectively. In addition, *ADGRE3* and *TNFRSF11A* were indicated to be co-expressed with *ALOX5AP* and *CD40LG*. The network also suggested that *TNFRSF11A* interacts and is co-expressed with *PFKCH* and *ADH1B*, respectively. Additionally, in the network, *FAM186A* was indirectly connected with CI-associated genes (*NPY* and *F5*) through *TMPRSS15*.

Discussion
==========

In the present study, genetic variants that confer susceptibility to CAD and CI were investigated. The longitudinal EWASs in a Japanese cohort identified that rs4606855 of *ADGRE3*, rs3746414 of *ZFP64* and rs7132908 of *FAIM2* were significantly associated with the prevalence of CAD, whereas rs6580741 of *FAM186A*, rs1324015 of *LINC00400* and rs884205 of *TNFRSF11A* were significantly associated with the prevalence of CI. According to the databases, these SNPs may be novel susceptibility loci for CAD or CI.

The adhesion G protein-coupled receptor E3 (*ADGRE3*) gene is located at chromosomal region 19p13.12, and rs4606855 \[G/C (E75Q)\] in this gene was significantly associated with the prevalence of CAD. The mRNA of *ADGRE3* is predominantly expressed in neutrophils, monocytes and macrophages, and this protein may be important for interactions between myeloid cells including neutrophils and monocytes during immune and inflammatory responses ([@b44-br-0-0-1109]). Given that vascular inflammatory responses serve a role in the development of coronary atherosclerosis and thrombosis ([@b45-br-0-0-1109]--[@b47-br-0-0-1109]), this CAD-associated SNP may be attributable to functional alteration of ADGRE3 protein in vascular inflammation.

The ZFP64 zinc finger protein (*ZFP64*) gene located at 20q13.2 is expressed in various tissues and organs, according to The Human Protein Atlas \[<http://www.proteinatlas.org/> ([@b48-br-0-0-1109],[@b49-br-0-0-1109])\]. The present longitudinal EWASs demonstrated that rs3746414 \[G/A (S451N)\] was significantly associated with the prevalence of CAD. ZFP64 protein may be a positive regulator of Toll-like receptor-induced innate immune responses through tumor necrosis factor (TNF)-α, interleukin-6 and interferon-β production in macrophages ([@b50-br-0-0-1109]). In fact, *Zfp64* knockdown mice exhibited significant reductions in the production of these cytokines ([@b50-br-0-0-1109]). Thus, the association of *ZFP64* with CAD may be attributable to the effect of this gene on the development of coronary atherosclerosis or thrombosis.

The Fas apoptotic inhibitory molecule 2 (*FAIM2*) gene is located at 12q13.12, and rs7132908 (G/A) in this gene was associated with the prevalence of CAD. *FAIM2* is predominantly expressed in the brain while moderate expressions are also observed in other various tissues and organs, according to The Human Protein Atlas. *AIM2* inhibits Fas-mediated apoptosis ([@b51-br-0-0-1109]). The Fas cell surface death receptor gene (*FAS*) serves important roles in the regulation of the immune system through inducing apoptosis of autoreactive or antigen-presenting T lymphocytes ([@b52-br-0-0-1109]--[@b54-br-0-0-1109]). Given that *FAIM2* regulates Fas-mediated apoptosis during immune responses, rs7132908 in this gene may be associated with the incidence of CAD through altering the regulation of immune or inflammatory responses.

The TNF receptor superfamily member 11a (*TNFRSF11A*) gene is located at chromosomal region 18q21.33, and is expressed in various tissues and organs including the brain, according to The Human Protein Atlas. In the present study, rs884205 (G/T) of *TNFRSF11A* was significantly associated with the prevalence of CI. *TNFRSF11A* and its ligand (*TNFRSF11*) may be important regulators of the interaction between T cells and dendritic cells that are involved in immune surveillance ([@b55-br-0-0-1109],[@b56-br-0-0-1109]). In mice, TNFRSF11/TNFRSF11A (also known as RANKL/RANK) signaling could trigger inflammatory fever responses in the central nervous system ([@b55-br-0-0-1109]), and may serve anti-inflammatory roles in ischemic brains ([@b56-br-0-0-1109]). The rs884205 in *TNFRSF11A* may thus influence the development of CI.

The exact functions of proteins encoded by the family with sequence similarity 186 member A (*FAM186A*) and long intergenic non-protein coding RNA 400 (*LINC00400*) genes are unknown. However, it has been reported that rs9533425 located near *LINC00400* at chromosomal region 13q14.11 demonstrated a significant association (P=1.9×10^−9^) with lag time to fibrin clot formation in 2,100 subjects from the Twins United Kingdom (TwinsUK) registry in stage 1 study, although the association of this SNP was not replicated in stage 2 study ([@b28-br-0-0-1109]). In the present longitudinal EWASs, rs1324015 of *LINC00400* was significantly associated with the prevalence of CI. According to LDpair in LDlink, rs1324015 was not in LD with rs9533425 in East Asian populations. Although the functional relevance of the candidate SNP to the development of cerebral atherosclerosis or thrombosis remains unclear, *LINC00400* may be a susceptibility locus for the incidence of CI.

There were certain limitations in the present study. First, the longitudinal EWASs were conducted in only a local Japanese population, and the observed number of patients who were affected by the target diseases was not sufficient. Thus, replication of longitudinal EWASs in other Japanese populations or other ethnic groups is required to verify the association of the identified SNPs with the diseases of interest. However, to the best of our knowledge, longitudinal data for CAD and CI in other populations are unavailable at present. Second, no experiments for functional analyses were conducted in the present study. Thus, the functional relevance of the candidate SNPs identified by longitudinal EWASs to the pathogenesis of the diseases of interest remains unclear. Due to the lack of experiments for functional analyses, the association of the SNPs identified in the present study with CAD or CI should be interpreted with caution. Further functional analyses are required to clarify the present results.

In conclusion, rs4606855 of *ADGRE3*, rs3746414 of *ZFP64* and rs7132908 of *FAIM2* may be susceptibility loci for CAD. Additionally, the SNPs rs6580741 of *FAM186A*, rs1324015 of *LINC00400* and rs884205 of *TNFRSF11A* may be genetic determinants of CI. All minor alleles of the six candidate SNPs exhibited an association with lower prevalence of the associated diseases, compared with the corresponding major alleles. This suggests that the minor alleles of each candidate SNP may be protective against CAD or CI.
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###### 

Longitudinal characteristics of study subjects in the Inabe cohort.

  Characteristic                                                     Control^[a](#tfn1-br-0-0-1109){ref-type="table-fn"}^   CAD^[a](#tfn1-br-0-0-1109){ref-type="table-fn"}^   CI^[a](#tfn1-br-0-0-1109){ref-type="table-fn"}^
  ------------------------------------------------------------------ ------------------------------------------------------ -------------------------------------------------- -------------------------------------------------
  No. of subjects^[b](#tfn2-br-0-0-1109){ref-type="table-fn"}^       5,713                                                  170                                                117
  Sex, male/female, %^[b](#tfn2-br-0-0-1109){ref-type="table-fn"}^   54.7/45.3                                              77.1/22.9                                          68.4/31.6
  Age, years                                                         52.0±0.07 (27,143)                                     63.1±0.41 (619)                                    63.4±0.35 (466)
  Body mass index, kg/m^2^                                           22.9±0.02 (26,719)                                     23.9±0.13 (507)                                    23.6±0.16 (416)
  Current or former smoker, %                                        38.4 (27,143)                                          40.1 (619)                                         35.0 (466)
  Hypertension, %                                                    31.9 (26,715)                                          75.7 (503)                                         65.1 (415)
  Systolic blood pressure, mmHg                                      120.4±0.10 (26,715)                                    126.5±0.77 (503)                                   127.6±0.81 (415)
  Diastolic blood pressure, mmHg                                     74.6±0.08 (26,715)                                     76.5±0.55 (503)                                    77.5±0.58 (415)
  Type 2 diabetes mellitus, %                                        11.4 (26,745)                                          38.8 (590)                                         36.4 (464)
  Fasting plasma glucose, mmol/l                                     5.59±0.007 (26,731)                                    6.49±0.086 (586)                                   6.22±0.098 (464)
  Blood hemoglobin A~1c~, %                                          5.69±0.004 (19,870)                                    6.18±0.052 (465)                                   6.03±0.041 (410)
  Dyslipidemia, %                                                    58.4 (26,713)                                          76.5 (592)                                         77.9 (444)
  Serum triglycerides, mmol/l                                        1.25±0.006 (26,710)                                    1.48±0.040 (591)                                   1.36±0.037 (444)
  Serum HDL-cholesterol, mmol/l                                      1.61±0.003 (26,687)                                    1.43±0.019 (585)                                   1.51±0.020 (440)
  Serum LDL-cholesterol, mmol/l                                      3.19±0.005 (25,594)                                    2.76±0.032 (563)                                   3.20±0.039 (422)
  Chronic kidney disease, %                                          10.8 (24,461)                                          37.6 (582)                                         37.0 (441)
  Serum creatinine, µmol/l                                           74.1±0.58 (24,461)                                     132.7±8.65 (582)                                   163.0±13.33 (441)
  eGFR, ml min^−1^ 1.73 m^−2^                                        79.2±0.11 (24,461)                                     66.1±1.11 (582)                                    64.5±1.31 (441)
  Hyperuricemia, %                                                   18.1 (23,985)                                          42.3 (575)                                         27.5 (436)
  Serum uric acid, µmol/l                                            327.7±0.56 (23,985)                                    367.3±4.20 (575)                                   352.7±4.09 (436)

Values in parentheses indicate the number of measurements taken

numbers based on examination data from the final visit for each subject. Quantitative data are presented as the mean and standard error of the mean. CAD, coronary artery disease; CI, cerebral infarction; HDL, high-density lipoprotein; LDL, low-density lipoprotein; eGFR, estimated glomerular filtration rate.

###### 

SNPs significantly (FDR \<0.05, approxdf \>30) associated with CAD or CI.

  Disease (genetic model)                                        RefSNP ID   Nucleotide (amino acid) substitution^[a](#tfn3-br-0-0-1109){ref-type="table-fn"}^   Position^[b](#tfn4-br-0-0-1109){ref-type="table-fn"}^   Gene          Estimate^[c](#tfn5-br-0-0-1109){ref-type="table-fn"}^   Std. err.    P-value         MAF     Apxdf^[d](#tfn6-br-0-0-1109){ref-type="table-fn"}^   FDR
  -------------------------------------------------------------- ----------- ----------------------------------------------------------------------------------- ------------------------------------------------------- ------------- ------------------------------------------------------- ------------ --------------- ------- ---------------------------------------------------- ---------------
  CAD (additive)^[e](#tfn7-br-0-0-1109){ref-type="table-fn"}^    rs4606855   G→C (E75Q)                                                                          19: 14,658,527                                          *ADGRE3*      −0.014                                                  0.003        2.5×10^−6^      0.120   71                                                   0.031
                                                                 rs3746414   G→A (S451N)                                                                         20: 52,152,840                                          *ZFP64*       −0.013                                                  0.003        5.9×10^−6^      0.140   93                                                   0.048
  CAD (recessive)^[f](#tfn8-br-0-0-1109){ref-type="table-fn"}^   rs7132908   G→A                                                                                 12: 49,869,365                                          *FAIM2*       −8.9×10^14^                                             2.2×10^13^   \<2.0×10^−16^   0.291   65                                                   \<4.9×10^−12^
  CI (recessive)^[f](#tfn8-br-0-0-1109){ref-type="table-fn"}^    rs6580741   G→C (H2228Q)                                                                        12: 50,333,923                                          *FAM186A*     −2.2×10^15^                                             2.2×10^13^   \<2.0×10^−16^   0.260   48                                                   \<4.9×10^−12^
                                                                 rs1324015   G→A                                                                                 13: 43,153,713                                          *LINC00400*   −40.22                                                  0.144        \<2.0×10^−16^   0.264   49                                                   \<4.9×10^−12^
                                                                 rs884205    G→T                                                                                 18: 62,387,624                                          *TNFRSF11A*   −40.12                                                  0.147        \<2.0×10^−16^   0.220   32                                                   \<4.9×10^−12^

Major allele → Minor allele
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estimate of correlation coefficient

approxdf = 2 × MAF × Nindep, where Nindep = the sum of the estimated number of independent observations per person

additive model \[AA vs. AB vs. BB (A, major allele; B, minor allele)\]

recessive model (AA + AB vs. BB). SNP, single nucleotide polymorphism; FDR, false discovery rate; CAD, coronary artery disease; CI, cerebral infarction; MAF, minor allele frequency; Std. err., standard error.

###### 

Genotype distributions for three candidate SNPs among subjects with CAD and controls.

  RefSNP ID   Position^[a](#tfn9-br-0-0-1109){ref-type="table-fn"}^   Gene       Genotype   Controls^[b](#tfn10-br-0-0-1109){ref-type="table-fn"}^   CAD^[b](#tfn10-br-0-0-1109){ref-type="table-fn"}^
  ----------- ------------------------------------------------------- ---------- ---------- -------------------------------------------------------- ---------------------------------------------------
  rs4606855   19: 14,658,527                                          *ADGRE3*   GG         21,095 (77.7)                                            564 (91.1)
                                                                                 GC         5,676 (20.9)                                             54 (8.7)
                                                                                 CC         372 (1.4)                                                1 (0.2)
  rs3746414   20: 52,152,840                                          *ZFP64*    GG         20,122 (74.1)                                            529 (85.5)
                                                                                 GA         6,506 (24.0)                                             81 (13.1)
                                                                                 AA         515 (1.9)                                                9 (1.5)
  rs7132908   12: 49,869,365                                          *FAIM2*    GG         13,609 (50.1)                                            344 (55.6)
                                                                                 GA         11,128 (41.0)                                            252 (40.7)
                                                                                 AA         2,406 (8.9)                                              23 (3.7)
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values indicate the numbers of measurements taken, with the percentages in parentheses. SNP, single nucleotide polymorphism; CAD, coronary artery disease.

###### 

Genotype distributions for three candidate SNPs among subjects with CI and controls.

  RefSNP ID   Position^[a](#tfn11-br-0-0-1109){ref-type="table-fn"}^   Gene          Genotype   Controls^[b](#tfn12-br-0-0-1109){ref-type="table-fn"}^   CI^[b](#tfn12-br-0-0-1109){ref-type="table-fn"}^
  ----------- -------------------------------------------------------- ------------- ---------- -------------------------------------------------------- --------------------------------------------------
  rs6580741   12: 50,333,923                                           *FAM186A*     GG         14,669 (54.1)                                            269 (57.7)
                                                                                     GC         10,555 (38.9)                                            171 (36.7)
                                                                                     CC         1,900 (7.0)                                              26 (5.6)
  rs1324015   13: 43,153,713                                           *LINC00400*   GG         14,809 (54.6)                                            295 (63.3)
                                                                                     GA         10,433 (38.5)                                            171 (36.7)
                                                                                     AA         1,882 (6.9)                                              0 (0.0)
  rs884205    18: 62,387,624                                           *TNFRSF11A*   GG         16,573 (61.1)                                            312 (67.0)
                                                                                     GT         9,154 (33.7)                                             154 (33.0)
                                                                                     TT         1,397 (5.2)                                              0 (0.0)
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values indicate the numbers of measurements taken, with the percentages in parentheses. SNP, single nucleotide polymorphism; CI, cerebral infarction.

###### 

Correlation estimates of candidate (query) SNPs with adjacent SNPs using LDproxy.

  Chr. pos.   RefSNP ID       r^2^   Chr. pos.   RefSNP ID       r^2^   Chr. pos.   RefSNP ID       r^2^
  ----------- --------------- ------ ----------- --------------- ------ ----------- --------------- ------
  18q21.33    **rs884205**    1.00   20q13.2     rs12481281      0.77   12q13.12    rs7979830       1.00
  13q14.11    **rs1324015**   1.00   20q13.2     rs3787176       0.77   12q13.12    rs35723625      1.00
  13q14.11    rs2589313       0.59   20q13.2     rs72626582      0.77   12q13.12    rs10876013      1.00
  13q14.11    rs1324016       0.57   20q13.2     rs72626583      0.77   12q13.12    rs12425229      1.00
  13q14.11    rs2762188       0.57   20q13.2     rs6021711       0.76   12q13.12    rs3812825       1.00
  13q14.11    rs2589314       0.57   20q13.2     rs2180366       0.76   12q13.12    rs1362983       1.00
  13q14.11    rs35574382      0.57   20q13.2     rs67904269      0.76   12q13.12    rs141978158     1.00
  13q14.11    rs2762185       0.57   20q13.2     rs7273288       0.74   12q13.12    rs7308095       1.00
  13q14.11    rs2657098       0.57   20q13.2     rs13045200      0.61   12q13.12    rs11169319      1.00
  13q14.11    rs1562123       0.57   20q13.2     rs11478756      0.61   12q13.12    rs12811291      1.00
  13q14.11    rs11424017      0.52   20q13.2     rs11473560      0.56   12q13.12    rs34825838      1.00
  20q13.2     rs3746414       1.00   20q13.2     rs6021739       0.56   12q13.12    rs11169317      1.00
  20q13.2     rs3746413       1.00   20q13.2     rs6096795       0.56   12q13.12    rs3861100       1.00
  20q13.2     rs3746415       1.00   20q13.2     rs6021738       0.56   12q13.12    rs11169315      1.00
  20q13.2     rs3787181       1.00   20q13.2     rs6021737       0.56   12q13.12    rs2009072       1.00
  20q13.2     rs11431529      1.00   20q13.2     rs6021736       0.56   12q13.12    rs11169314      1.00
  20q13.2     rs67642347      1.00   20q13.2     rs6013400       0.56   12q13.12    rs6580739       0.97
  20q13.2     rs4809893       1.00   20q13.2     rs6096794       0.56   12q13.12    rs7972824       0.97
  20q13.2     rs8122116       1.00   20q13.2     rs6013399       0.56   12q13.12    rs9739363       0.97
  20q13.2     rs6021732       1.00   20q13.2     rs117265881     0.56   12q13.12    rs12823506      0.97
  20q13.2     rs2224227       1.00   20q13.2     rs4809892       0.51   12q13.12    rs112456855     0.97
  20q13.2     rs66953446      1.00   20q13.2     rs145753021     0.51   12q13.12    rs12422417      0.97
  20q13.2     rs115523244     1.00   19p13.12    **rs4606855**   1.00   12q13.12    rs35224873      0.97
  20q13.2     rs6021723       1.00   19p13.12    rs56819877      1.00   12q13.12    rs12828340      0.87
  20q13.2     rs12480406      1.00   19p13.12    rs4808971       1.00   12q13.12    rs17124562      0.87
  20q13.2     rs67638808      1.00   19p13.12    rs7255012       1.00   12q13.12    rs11169335      0.87
  20q13.2     rs67262858      1.00   19p13.12    rs10426121      1.00   12q13.12    rs35576436      0.87
  20q13.2     rs6013397       1.00   19p13.12    rs6511956       1.00   12q13.12    rs11169332      0.87
  20q13.2     rs12481222      0.97   19p13.12    rs4273164       1.00   12q13.12    rs11169331      0.87
  20q13.2     rs139218250     0.97   19p13.12    rs4239642       1.00   12q13.12    rs71465002      0.87
  20q13.2     rs7346642       0.97   19p13.12    rs10402993      0.95   12q13.12    rs7314465       0.87
  20q13.2     rs67892028      0.97   19p13.12    rs11085902      0.95   12q13.12    rs6580730       0.87
  20q13.2     rs73130324      0.97   19p13.12    rs11085901      0.95   12q13.12    rs7308885       0.87
  20q13.2     rs75085690      0.97   19p13.12    rs7245656       0.86   12q13.12    rs2358539       0.87
  20q13.2     rs3838014       0.94   19p13.12    rs7250114       0.86   12q13.12    rs201343445     0.87
  20q13.2     rs3179313       0.94   19p13.12    rs73506161      0.86   12q13.12    rs12424713      0.87
  20q13.2     rs3179314       0.94   19p13.12    rs35805282      0.86   12q13.12    rs12424691      0.87
  20q13.2     rs3787178       0.94   19p13.12    rs75540045      0.86   12q13.12    rs11169322      0.87
  20q13.2     rs1555328       0.94   19p13.12    rs34930135      0.86   12q13.12    rs12425705      0.87
  20q13.2     rs6021748       0.94   19p13.12    rs373306807     0.66   12q13.12    rs35628283      0.87
  20q13.2     rs6021747       0.94   12q13.12    **rs6580741**   1.00   12q13.12    rs35875720      0.87
  20q13.2     rs4811297       0.94   12q13.12    rs7310541       1.00   12q13.12    rs34198664      0.84
  20q13.2     rs111897744     0.94   12q13.12    rs7134337       1.00   12q13.12    rs11292692      0.82
  20q13.2     rs6021745       0.94   12q13.12    rs7134595       1.00   12q13.12    rs4768905       0.77
  20q13.2     rs6021744       0.94   12q13.12    rs55931113      1.00   12q13.12    rs59210472      0.77
  20q13.2     rs6021743       0.94   12q13.12    rs35878271      1.00   12q13.12    rs4636745       0.77
  20q13.2     rs6021742       0.94   12q13.12    rs34039674      1.00   12q13.12    rs11830586      0.77
  20q13.2     rs6021741       0.94   12q13.12    rs66895907      1.00   12q13.12    rs7973910       0.77
  20q13.2     rs6021740       0.94   12q13.12    rs4768900       1.00   12q13.12    rs73305103      0.77
  20q13.2     rs6021735       0.94   12q13.12    rs10876020      1.00   12q13.12    rs4321029       0.77
  20q13.2     rs6021734       0.94   12q13.12    rs34858415      1.00   12q13.12    rs7968898       0.77
  20q13.2     rs56783695      0.94   12q13.12    rs11836169      1.00   12q13.12    rs151015253     0.77
  20q13.2     rs60610902      0.94   12q13.12    rs4768949       1.00   12q13.12    rs11169323      0.74
  20q13.2     rs6021733       0.94   12q13.12    rs4768872       1.00   12q13.12    rs73305105      0.74
  20q13.2     rs60614585      0.94   12q13.12    rs34614542      1.00   12q13.12    rs35925338      0.74
  20q13.2     rs57913961      0.94   12q13.12    rs12312177      1.00   12q13.12    NA              0.72
  20q13.2     rs6021730       0.94   12q13.12    rs34894919      1.00   12q13.12    rs144615146     0.72
  20q13.2     rs6021729       0.94   12q13.12    rs12424876      1.00   12q13.12    rs78601155      0.72
  20q13.2     rs6021728       0.94   12q13.12    rs11169377      1.00   12q13.12    rs74336127      0.72
  20q13.2     rs6021727       0.94   12q13.12    rs11169376      1.00   12q13.12    rs141852922     0.69
  20q13.2     rs6096791       0.94   12q13.12    rs36017775      1.00   12q13.12    rs145504356     0.69
  20q13.2     rs6091458       0.94   12q13.12    rs11169375      1.00   12q13.12    rs34098872      0.65
  20q13.2     rs6091457       0.94   12q13.12    rs7137319       1.00   12q13.12    rs67576611      0.64
  20q13.2     rs200887094     0.94   12q13.12    rs7295847       1.00   12q13.12    rs7138622       0.64
  20q13.2     rs6096784       0.94   12q13.12    rs7296291       1.00   12q13.12    rs7138420       0.64
  20q13.2     rs77290230      0.94   12q13.12    rs7312252       1.00   12q13.12    rs7315690       0.64
  20q13.2     rs12624632      0.94   12q13.12    rs10506292      1.00   12q13.12    rs5798135       0.63
  20q13.2     rs6021722       0.94   12q13.12    rs34849043      1.00   12q13.12    rs17124514      0.62
  20q13.2     rs6091453       0.94   12q13.12    rs10615610      1.00   12q13.12    rs12424335      0.62
  20q13.2     rs6021721       0.94   12q13.12    rs10876023      1.00   12q13.12    rs34145380      0.62
  20q13.2     rs6021720       0.94   12q13.12    rs10876024      1.00   12q13.12    rs34309034      0.62
  20q13.2     rs6512796       0.94   12q13.12    rs7301186       1.00   12q13.12    rs34245511      0.62
  20q13.2     rs12480343      0.93   12q13.12    rs11169374      1.00   12q13.12    rs9364          0.62
  20q13.2     rs12480321      0.93   12q13.12    rs11169373      1.00   12q13.12    rs8181651       0.60
  20q13.2     rs67451131      0.93   12q13.12    rs35209607      1.00   12q13.12    rs80003859      0.60
  20q13.2     rs6013393       0.93   12q13.12    rs4421818       1.00   12q13.12    rs144939089     0.60
  20q13.2     rs67862732      0.93   12q13.12    rs11169370      1.00   12q13.12    rs28364704      0.59
  20q13.2     rs144698812     0.93   12q13.12    rs11169369      1.00   12q13.12    rs736167        0.59
  20q13.2     rs117427009     0.93   12q13.12    rs11169390      1.00   12q13.12    rs10783347      0.59
  20q13.2     rs140670817     0.93   12q13.12    rs11169391      1.00   12q13.12    rs10783346      0.59
  20q13.2     rs6021709       0.93   12q13.12    rs4445717       1.00   12q13.12    rs61928279      0.59
  20q13.2     rs6021708       0.93   12q13.12    rs9668187       1.00   12q13.12    rs7302422       0.59
  20q13.2     rs72626578      0.93   12q13.12    rs60025018      1.00   12q13.12    rs12423130      0.59
  20q13.2     rs6021707       0.93   12q13.12    rs11169393      1.00   12q13.12    rs3815671       0.59
  20q13.2     rs6021706       0.93   12q13.12    rs10467106      1.00   12q13.12    rs57583527      0.59
  20q13.2     rs140980517     0.93   12q13.12    rs12303082      1.00   12q13.12    rs10747572      0.59
  20q13.2     rs143481833     0.93   12q13.12    rs7971374       1.00   12q13.12    rs71083515      0.57
  20q13.2     rs12624823      0.93   12q13.12    rs10783352      1.00   12q13.12    rs79043170      0.55
  20q13.2     rs12624819      0.93   12q13.12    rs10783353      1.00   12q13.12    rs35404088      0.55
  20q13.2     rs148218979     0.93   12q13.12    rs12299758      1.00   12q13.12    rs10783340      0.55
  20q13.2     rs6021760       0.90   12q13.12    rs12299669      1.00   12q13.12    rs7978904       0.55
  20q13.2     rs3818198       0.90   12q13.12    rs11169394      1.00   12q13.12    rs10783338      0.55
  20q13.2     rs72626580      0.90   12q13.12    rs11169395      1.00   12q13.12    rs7398567       0.55
  20q13.2     rs4811301       0.90   12q13.12    rs11169367      1.00   12q13.12    rs10735824      0.55
  20q13.2     rs4811303       0.90   12q13.12    rs11833608      1.00   12q13.12    rs7972465       0.55
  20q13.2     rs4811304       0.90   12q13.12    rs113486728     1.00   12q13.12    rs6580728       0.55
  20q13.2     rs4811305       0.90   12q13.12    rs376666931     1.00   12q13.12    rs7138945       0.55
  20q13.2     rs140407501     0.90   12q13.12    rs7980911       1.00   12q13.12    rs11169282      0.55
  20q13.2     rs6021763       0.90   12q13.12    rs7302363       1.00   12q13.12    rs57061317      0.53
  20q13.2     rs6021764       0.90   12q13.12    rs4768855       1.00   12q13.12    rs76382737      0.53
  20q13.2     rs6021765       0.90   12q13.12    rs6580737       1.00   12q13.12    rs12369104      0.53
  20q13.2     rs6021766       0.90   12q13.12    rs7488682       1.00   12q13.12    rs12819883      0.53
  20q13.2     rs11480360      0.90   12q13.12    rs7972068       1.00   12q13.12    rs3741562       0.53
  20q13.2     rs6021767       0.90   12q13.12    rs7972202       1.00   12q13.12    rs113411336     0.53
  20q13.2     rs6021768       0.90   12q13.12    rs6580743       1.00   12q13.12    rs34632215      0.53
  20q13.2     rs6013409       0.90   12q13.12    rs4348979       1.00   12q13.12    rs11169278      0.53
  20q13.2     rs6021770       0.90   12q13.12    rs11169360      1.00   12q13.12    rs1554845       0.53
  20q13.2     rs2038429       0.90   12q13.12    rs11169359      1.00   12q13.12    rs2204684       0.53
  20q13.2     rs6021772       0.90   12q13.12    rs12814094      1.00   12q13.12    rs2204683       0.53
  20q13.2     rs2273472       0.90   12q13.12    rs7315955       1.00   12q13.12    rs10876000      0.53
  20q13.2     rs2038430       0.90   12q13.12    rs11169357      1.00   12q13.12    rs7967979       0.53
  20q13.2     rs6021774       0.90   12q13.12    rs10876028      1.00   12q13.12    rs34167640      0.53
  20q13.2     rs58878184      0.90   12q13.12    rs7135777       1.00   12q13.12    rs7307469       0.53
  20q13.2     rs72626581      0.90   12q13.12    rs11838347      1.00   12q13.12    rs1554844       0.53
  20q13.2     rs34963386      0.90   12q13.12    rs12426444      1.00   12q13.12    rs7961065       0.53
  20q13.2     NA              0.90   12q13.12    rs9705460       1.00   12q13.12    rs7961112       0.53
  20q13.2     rs6021775       0.90   12q13.12    rs7304445       1.00   12q13.12    rs7294618       0.53
  20q13.2     rs1973951       0.90   12q13.12    rs11323536      1.00   12q13.12    rs7307230       0.53
  20q13.2     rs77286509      0.90   12q13.12    rs7311973       1.00   12q13.12    rs7135322       0.53
  20q13.2     rs7265436       0.90   12q13.12    rs10876017      1.00   12q13.12    rs59262224      0.53
  20q13.2     rs6096760       0.90   12q13.12    rs10876016      1.00   12q13.12    rs17124432      0.53
  20q13.2     rs142762031     0.87   12q13.12    rs7974648       1.00   12q13.12    rs12369049      0.53
  20q13.2     rs138459074     0.87   12q13.12    rs12821454      1.00   12q13.12    rs7308474       0.53
  20q13.2     rs67243058      0.84   12q13.12    rs7305995       1.00   12q13.12    rs7968119       0.53
  20q13.2     rs6021731       0.82   12q13.12    rs35933908      1.00   12q13.12    rs61529910      0.51
  20q13.2     rs6013396       0.79   12q13.12    rs12832940      1.00   12q13.12    NA              0.50
  20q13.2     rs6021719       0.79   12q13.12    rs10876015      1.00   12q13.12    **rs7132908**   1.00
  20q13.2     rs6021718       0.79   12q13.12    rs10876014      1.00   12q13.12    rs3205718       1.00
  20q13.2     rs6091452       0.79   12q13.12    rs67138019      1.00   12q13.12    rs12146733      0.98
  20q13.2     rs6091451       0.79   12q13.12    rs11169351      1.00   12q13.12    rs1893492       0.98
  20q13.2     rs6126474       0.79   12q13.12    rs11169350      1.00   12q13.12    rs145103902     0.98
  20q13.2     rs6123134       0.79   12q13.12    rs11169349      1.00   12q13.12    rs73116325      0.98
  20q13.2     rs8121769       0.79   12q13.12    rs35535298      1.00   12q13.12    rs146875448     0.85
  20q13.2     rs6021716       0.79   12q13.12    rs2111988       1.00   12q13.12    rs11169199      0.80
  20q13.2     rs6021715       0.79   12q13.12    rs7311491       1.00   12q13.12    rs297924        0.80
  20q13.2     rs6123133       0.79   12q13.12    rs7311378       1.00   12q13.12    rs17201502      0.80
  20q13.2     rs6096776       0.79   12q13.12    rs11169348      1.00   12q13.12    rs73116335      0.80
  20q13.2     rs62216897      0.79   12q13.12    rs6580735       1.00   12q13.12    rs73116338      0.80
  20q13.2     rs6126472       0.79   12q13.12    rs11169347      1.00   12q13.12    rs73116339      0.80
  20q13.2     rs7265434       0.79   12q13.12    rs11169345      1.00   12q13.12    rs145512623     0.75
  20q13.2     rs7273176       0.79   12q13.12    rs7956468       1.00   12q13.12    NA              0.59
  20q13.2     rs7273121       0.79   12q13.12    rs1972611       1.00   12q13.12    rs149596227     0.57
  20q13.2     rs8183138       0.79   12q13.12    rs10783344      1.00   12q13.12    rs373555454     0.55
  20q13.2     rs6123131       0.79   12q13.12    rs35768991      1.00   12q13.12    rs12367809      0.53
  20q13.2     rs79718879      0.79   12q13.12    rs11169339      1.00   12q13.12    rs7306275       0.51
  20q13.2     rs76931275      0.79   12q13.12    rs7486747       1.00   12q13.12    rs7138803       0.50
  20q13.2     rs6021714       0.79   12q13.12    rs7953953       1.00   12q13.12    rs112502508     0.50
  20q13.2     rs6021713       0.79   12q13.12    rs7132551       1.00                               

SNPs with r^2^\>0.5 only are shown. The candidate SNPs identified in the present study are shown in bold. SNP, single nucleotide polymorphism; Chr. pos., chromosomal position; NA, not available.
